EGFR and neoplasm: Inhibiting IL6 can enhance antitumor immunity and sensitize EGFRmut tumors to anti‐PD‐1 therapeutic efficacy via increasing tumor‐infiltrating IFNγ+ CD8+ T cells.[283] And tumor cells express lncRNA (LINC00973) through EGFR/Wnt signaling, which increases CD55/CD59 expression and inhibits the secretion of cytokines required for CD8+ T cell activation.